12.11

1.68% 0.20

After Hours: 12.11

Stoke Therapeutics Inc (STOK)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Stoke Therapeutics Inc stock is traded at $12.11, with a volume of 173.81K. It is up +1.68% in the last 24 hours and down -2.34% over the past month. Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Previous Close:

$11.91

Open:

$11.99

24h Volume:

173.81K

Relative Volume:

0.35

Market Cap:

$641.43M

Revenue:

$8.78M

Net Income/Loss:

$-104.70M

P/E Ratio:

-4.7866

EPS:

-2.53

Net Cash Flow:

$-82.68M

1W Performance:

+5.95%

1M Performance:

-2.34%

6M Performance:

-12.06%

1Y Performance:

+214.55%

1-Day Range:

$11.81

$12.27

1-Week Range:

$11.51

$12.27

52-Week Range:

$3.77

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Name

Stoke Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

781-430-8200

Address

45 WIGGINS AVENUE, BEDFORD, MA

Employee

110

Twitter

@stoketx

Next Earnings Date

2024-11-05

Latest SEC Filings

STOK's Discussions on Twitter

Compare STOK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
STOK Stoke Therapeutics Inc	12.11	641.43M	8.78M	-104.70M	-82.68M	-2.37
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-14-24	Resumed	Leerink Partners	Outperform
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral
Apr-26-23	Resumed	Canaccord Genuity	Buy
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-31-22	Initiated	Jefferies	Buy
Dec-03-21	Initiated	BofA Securities	Buy
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight
May-18-21	Initiated	UBS	Neutral
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy
Dec-11-20	Reiterated	Needham	Buy
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight
Sep-29-20	Resumed	JP Morgan	Neutral
Sep-29-20	Initiated	Needham	Buy
Dec-18-19	Initiated	Wedbush	Outperform
Nov-12-19	Initiated	BTIG Research	Buy
Oct-25-19	Initiated	H.C. Wainwright	Buy
Jul-15-19	Initiated	Canaccord Genuity	Buy
Jul-15-19	Initiated	Cowen	Outperform
Jul-15-19	Initiated	Credit Suisse	Outperform
Jul-15-19	Initiated	JP Morgan	Overweight

View All

Stoke Therapeutics Inc Stock (STOK) Latest News

Nov 26, 2024

Stoke Therapeutics: First Disease Modifying Therapy For Dravet, Still In Need Of Regulatory Clarity (NASDAQ:STOK) - Seeking Alpha

Nov 26, 2024

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - PharmaVoice

Nov 26, 2024

Nov 21, 2024

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN

Nov 21, 2024

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average PT from Analysts - MarketBeat

Nov 17, 2024

Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages - Defense World

Nov 17, 2024

Los Angeles Capital Management LLC Grows Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - MarketBeat

Nov 15, 2024

Nov 14, 2024

Lynx1 Capital Management LP's Strategic Acquisition in Stoke The - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade - MSN

Nov 12, 2024

Nov 09, 2024

FY2024 EPS Forecast for Stoke Therapeutics Lifted by Analyst - Defense World

Nov 09, 2024

Nov 08, 2024

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St

Nov 08, 2024

Wedbush Lifts Earnings Estimates for Stoke Therapeutics - MarketBeat

Nov 08, 2024

Research Analysts Offer Predictions for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Research Analysts Set Expectations for STOK FY2024 Earnings - MarketBeat

Nov 08, 2024

Nov 06, 2024

Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Needham & Company LLC - MarketBeat

Nov 06, 2024

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts - Simply Wall St

Nov 06, 2024

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues - Yahoo Finance

Nov 06, 2024

Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 06, 2024

Nov 05, 2024

Stoke Therapeutics Reports Q3 Results, Focuses on Phase 3 Study - TipRanks

Nov 05, 2024

Stoke Therapeutics (NASDAQ:STOK) Trading Down 4.1%Time to Sell? - MarketBeat

Nov 05, 2024

Stoke Therapeutics earnings beat by $0.07, revenue topped estimates - Investing.com Canada

Nov 05, 2024